-_-行走-_-
He liked
USD/JPY: WAVE ANALYSIS
ScenarioTimeframeWeeklyRecommendationBUYEntry Point153.21Take Profit157.00, 161.50Stop Loss151.53Key Levels148.27, 150.22, 151.53, 157.00, 161.50Alternative scenarioRecommendationSELL STOPEntry Point151.50Take Profit150.22, 148.27Stop Loss152.10Key Levels148.27, 150.22, 151.53, 157.00, 161.50Growth
He liked
Profit by Following
190.69
USD
- Symbol XAU/USD
- Trading Account #1 693075105
- Broker ATFX
- Open/Close price 2,245/2,257.07
- Volume Buy 0.11 Flots
- Profit 132.77 USD
He liked
He liked
ALIBABA GROUP HOLDINGS LTD.: ANALISIS GELOMBANG
SkenarioJangka waktuMingguanRekomendasiMENJUALTitik masuk76.39Mengambil keuntungan60.00, 50.00Hentikan Kerugian79.00Tingkat Kunci50.00, 60.00, 79.00, 89.50, 103.00Skenario alternatifRekomendasiBELI BERHENTITitik masuk79.05Mengambil keuntungan89.50, 103.00Hentikan Kerugian75,55Tingkat Kunci50.00, 60.
He liked
He liked
He liked
He liked
He liked
He liked
礼来推出减肥药配送服务,警告不要为美而服药,股价创历史新高
减肥药生产商礼来(Eli Lilly & Co.)美东时间周四宣布推出针对家庭配送减肥药等特选药品的数字医疗保健平台,促使该公司股价一度涨超2%,盘中创历史新高。不过,礼来同时警告消费者,其广受欢迎的糖尿病和肥胖药物Mounjaro和Zepbound不应用于“美容减重”,因为近期这些药物的仿单标示外使用(off-label use)情况激增,可能出现供应短缺。 礼来周四宣布推出针对家庭配送肥胖症、偏头痛、糖尿病患者特选药品领域推出数字医疗保健平台LillyDirect,促使该公司股价一度上涨超过2.2%,突破2023年10月13日顶部629.97美元,刷新盘中历史高位至631美元上方,
He liked
Pull-up Update